摘要
目的:探讨儿童抽动障碍(TD)的中西结合疗法。方法:选取我院2024年收治的TD患儿88例,以随机数表法分为常规组和联合组各44例,常规组采用盐酸硫必利+维生素D_(3)治疗,联合组在常规组基础上联用菖麻熄风片治疗。比较两组患儿的治疗效果、中医证候积分、儿童行为量表(CBCL)评分、耶鲁综合抽动严重程度量表(YGTSS)评分、血清多巴胺(DA)、5-羟色胺(5-HT)、25羟基维生素D[25(OH)D]水平、复发率及不良反应发生率。结果:治疗后,两组患儿中医证候积分、CBCL评分、YGTSS总评分、DA、5-HT水平均下降,25(OH)D水平均升高,且联合组改善程度均大于常规组(P均<0.05)。联合组总有效率为93.18%,高于常规组的77.27%(P<0.05);联合组复发率为4.76%,低于常规组的21.95%(P<0.05);联合组不良反应发生率为13.64%,与常规组的15.91%比较,差异无统计学意义(P>0.05)。结论:采用菖麻熄风片+盐酸硫必利+维生素D_(3)治疗儿童TD,可提高临床疗效,减少复发,且未增加不良反应风险,值得临床推广应用。
Objective:To explore the treatment of integrated traditional Chinese medicine and Western medicine in the treatment of children with tic disorders(TD).Methods:A total of 88 children with TD admitted into our hospital in 2024 were extracted to be divided into the conventional group and combined group via the random number table method,with 44 cases in each group.The conventional group received tiapride hydrochloride+vitamin D_(3),and the combined group was given Changma Xifeng tablets based on the conventional group.The therapeutic effects,traditional Chinese medicine syndrome scores,Children Behavior Checklist(CBCL)scores,Yale Global Tics Severity Scale(YGTSS)scores,serum dopamine(DA),5-hydroxytryptamine(5-HT),25-hydroxyvitamin D[25(OH)D]levels,recurrence rates and adverse drug reaction of two groups were compared.Results:After treatment,the traditional Chinese medicine syndrome scores,CBCL scores,YGTSS scores,DA,and 5-HT levels in both groups decreased,while 25(OH)D levels increased,the improvement in the combined group was greater than that in the conventional group(P<0.05).The total effective rate of combined group was 93.18%,higher than 77.27%of conventional group(P<0.05);the recurrence rate of combined group was 4.76%,lower than 21.95%of conventional group(P<0.05);the incidence of adverse drug reactions in combined group was 13.64%,lower than 15.91%in conventional group(P>0.05).Conclusion:Changma Xifeng tablets combined with tiapride hydrochloride and vitamin D_(3) in the treatment of children with TD can enhance the clinical efficacy,reduce the recurrence rate,without increasing the adverse drug reactions,which is worthy of clinical promotion and application.
作者
李晓敏
闫玉姣
卢东娥
Li Xiaomin;Yan Yujiao;Lu Dong’e(Handan Maternal and Child Health Hospital,Hebei Handan 056000,China)
出处
《儿科药学杂志》
2026年第1期16-19,共4页
Journal of Pediatric Pharmacy
基金
河北省卫生健康委员会资助项目,编号20251315。
